Catalent boosts nutraceuticals market presence with $1 billion Bettera acquisition

The transaction is expected to accelerate Catalent's growth in global softgel and oral dose formulation and manufacturing services

Taking advantage of the rapidly expanding consumer health and nutraceutical marketplace, Catalent has agreed to acquire Bettera Holdings for $1 billion.

Bettera has four production facilities in the US (California, Indiana, New Jersey, and Virginia), and is a major manufacturer in the gummy, soft chew, and lozenge segments of the nutritional supplements market. The company boasts broad and specialised expertise in successfully developing and producing consumer-preferred products for nutraceutical, functional, and botanical ingredients.

According to Dr Aris Gennadios, President, Softgel and Oral Technologies at Catalent, these sectors are experiencing double-digit growth, and the Bettera acquisition will complement and accelerate the growth of Catalet's global softgel and oral dose formulation and manufacturing business.

“This acquisition is a key strategic move for Catalent’s Consumer Health business, where our leadership in manufacturing technologies and formulation can offer customers more product development opportunities and add manufacturing capacity in this dynamic and fast-growing segment," he said.

Specifically, the transaction will enable Catalent to expand its current consumer health technology platform with a wider range of technologies and ready-to-market product libraries, as well as a variety of packaging options to meet customers’ branding needs.

Bettera will complement and leverage Catalent’s network of consumer health manufacturing sites across North and South America, Europe, and Japan, offering formulation development, delivery and supply solutions to the global consumer health and beauty markets. The combination will unlock significant commercial synergies as Catalent brings the offerings of each company to their respective customer bases.

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and global reliable supply. Our team of nearly 13,000, including approximately 2,400 scientists at o...

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity

Contract Service; Manufacturer/Innovator